Dolors Rodríguez-Pardo1,2,3, María Dolores Del Toro4,5,6, Laura Guío-Carrión4,5,7, Rosa Escudero-Sánchez5,8, Marta Fernández-Sampedro4,5,9, Miguel Ángel García-Viejo5,10, María Velasco-Arribas5,11, Laura Soldevila-Boixader5,12, Magdalena Femenias13, José Antonio Iribarren5,14, María Del Carmen Pulido-Garcia15, María Dolores Navarro4,5,6, Mayli Lung4,5,16, Pablo S Corona4,5,17, Benito Almirante18,4,5, Carles Pigrau18,4,5. 1. Infectious Diseases Department, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Pg. Vall d'Hebron 119-129, 08035, Barcelona, Spain. dolorodriguez@vhebron.net. 2. Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0003), Instituto de Salud Carlos III, Madrid, Spain. dolorodriguez@vhebron.net. 3. Study Group on Osteoarticular Infections of the Spanish Society of Clinical Microbiology and Infectious Diseases (GEIO-SEIMC), Madrid, Spain. dolorodriguez@vhebron.net. 4. Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0003), Instituto de Salud Carlos III, Madrid, Spain. 5. Study Group on Osteoarticular Infections of the Spanish Society of Clinical Microbiology and Infectious Diseases (GEIO-SEIMC), Madrid, Spain. 6. Infectious Diseases Unit, Hospital Universitario Virgen Macarena, Departamento de Medicina, Universidad de Sevilla, Instituto de Biomedicina de Sevilla (IBiS), Seville, Spain. 7. Infectious Diseases Department, Hospital Universitario Cruces, Barakaldo, Vizcaya, Spain. 8. Infectious Diseases Department, Hospital Universitario Ramón y Cajal, Madrid, Spain. 9. Infectious Diseases Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain. 10. Internal Medicine Department, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain. 11. Internal Medicine Department (Infectious Diseases Division), Hospital Universitario Fundación Alcorcón, Madrid, Spain. 12. Infectious Diseases Department, Hospital Universitari de Bellvitge, Barcelona, Spain. 13. Orthopedic Surgery Department, Hospital Universitario Son Espases, Palma de Mallorca, Spain. 14. Infectious Diseases Department, Hospital Universitario Donostia IIS Biodonostia, San Sebastián, Spain. 15. Orthopedic Surgery Department, Hospital Santa Creu i Sant Pau, Barcelona, Spain. 16. Microbiology Department, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain. 17. Septic and Reconstructive Surgery Unit, Orthopedic Surgery Department, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain. 18. Infectious Diseases Department, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Pg. Vall d'Hebron 119-129, 08035, Barcelona, Spain.
Abstract
PURPOSE: To evaluate preoperative asymptomatic bacteriuria (ASB) treatment to reduce early-periprosthetic joint infections (early-PJIs) after hip hemiarthroplasty (HHA) for fracture. METHODS: Open-label, multicenter RCT comparing fosfomycin-trometamol versus no intervention with a parallel follow-up cohort without ASB. PRIMARY OUTCOME: early-PJI after HHA. RESULTS: Five hundred ninety-four patients enrolled (mean age 84.3); 152(25%) with ASB (77 treated with fosfomycin-trometamol/75 controls) and 442(75%) without. Despite the study closed without the intended sample size, ASB was not predictive of early-PJI (OR: 1.06 [95%CI: 0.33-3.38]), and its treatment did not modify early-PJI incidence (OR: 1.03 [95%CI: 0.15-7.10]). CONCLUSIONS: Neither preoperative ASB nor its treatment appears to be risk factors of early-PJI after HHA. ClinicalTrials.gov Identifier: Eudra CT 2016-001108-47.
PURPOSE: To evaluate preoperative asymptomatic bacteriuria (ASB) treatment to reduce early-periprosthetic joint infections (early-PJIs) after hip hemiarthroplasty (HHA) for fracture. METHODS: Open-label, multicenter RCT comparing fosfomycin-trometamol versus no intervention with a parallel follow-up cohort without ASB. PRIMARY OUTCOME: early-PJI after HHA. RESULTS: Five hundred ninety-four patients enrolled (mean age 84.3); 152(25%) with ASB (77 treated with fosfomycin-trometamol/75 controls) and 442(75%) without. Despite the study closed without the intended sample size, ASB was not predictive of early-PJI (OR: 1.06 [95%CI: 0.33-3.38]), and its treatment did not modify early-PJI incidence (OR: 1.03 [95%CI: 0.15-7.10]). CONCLUSIONS: Neither preoperative ASB nor its treatment appears to be risk factors of early-PJI after HHA. ClinicalTrials.gov Identifier: Eudra CT 2016-001108-47.
Authors: Ricardo Sousa; Ernesto Muñoz-Mahamud; Jonathan Quayle; Luis Dias da Costa; Cristina Casals; Phylip Scott; Pedro Leite; Paz Vilanova; Sebastian Garcia; Maria Helena Ramos; Joana Dias; Alex Soriano; Andrea Guyot Journal: Clin Infect Dis Date: 2014-04-09 Impact factor: 9.079
Authors: Lindsay E Nicolle; Kalpana Gupta; Suzanne F Bradley; Richard Colgan; Gregory P DeMuri; Dimitri Drekonja; Linda O Eckert; Suzanne E Geerlings; Béla Köves; Thomas M Hooton; Manisha Juthani-Mehta; Shandra L Knight; Sanjay Saint; Anthony J Schaeffer; Barbara Trautner; Bjorn Wullt; Reed Siemieniuk Journal: Clin Infect Dis Date: 2019-05-02 Impact factor: 9.079
Authors: David Hernández-Hernández; Bárbara Padilla-Fernández; María Yanira Ortega-González; David Manuel Castro-Díaz Journal: Curr Bladder Dysfunct Rep Date: 2021-12-01